As­traZeneca's Ul­tomiris hits pri­ma­ry end­point for PhI­II NMOSD study

As­traZeneca caught a trio of re­cent wins — scor­ing an ex­pand­ed in­di­ca­tion for its breast can­cer drug En­her­tu, nail­ing Farx­i­ga’s Phase III win ear­li­er this week …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER